<DOC>
	<DOCNO>NCT02064725</DOCNO>
	<brief_summary>This open label , multi-center , single arm phase II study . The study investigate efficacy sodium cridanimod conjunction progestin therapy population patient recurrent persistent PrR-negative endometrial cancer .</brief_summary>
	<brief_title>Virexxa ( Sodium Cridanimod ) w/Progestin Therapy Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA</brief_title>
	<detailed_description>This open label , multi-center , single arm phase II study . The study investigate efficacy sodium cridanimod conjunction progestin therapy population patient recurrent persistent PrR-negative endometrial cancer . Eligible patient enrol study administer sodium cridanimod combination progestin therapy . Objective response assess 12 week interval . Patients treat 12 month period , follow additional 12 month follow period disease progression whichever occur first . Important objective study investigate effect sodium cridanimod conjunction progestin therapy level PrR tumor tissue correlate efficacy . To accomplish objective , patient enrol study undergo two tumor biopsy allow measurement PrR level tumor tissue treatment 4 week therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<criteria>Female patient age 18 old ; Histologically confirm papillary serous adenocarcinoma endometrioid type endometrial carcinoma ( histological documentation recurrence require ) ; Patient document evidence PrR negative endometrial cancer . PrR negativity determine immunohistochemistry . The tumor consider PrR negative number PrR positive cell less 1 % determined immunohistochemistry ; Availability tumor tissue sample use assessment PrR level use immunohistochemistry ; Recurrent persistent ( failure chemotherapy ) disease treat surgery radiotherapy ; Documented disease progression platinum base chemotherapy patient administration taxanes anthracyclines plan . Progression must fulfill one follow criterion : Progression occur within 30 day platinum base chemotherapy consist minimum two cycle cisplatinbased ( ≥60 mg/m2/cycle ) carboplatinbased ( ≥300 mg/m2/cycle , area timeconcentration curve ≥4 ) chemotherapy . Progression neoadjuvant adjuvant platinum base chemotherapy recurrence occur neoadjuvant/adjuvant chemotherapy within 6 month since last administration therapy . Measurable disease define RECIST 1.1 criterion ; At least one `` target lesion '' use assess response , define RECIST 1.1 criterion ; Tumors within previously irradiate field designate `` nontarget '' lesion unless progression document ; GOG performance status 02 ; Glomerular filtration rate ≥ 50 mL/min ; Total bilirubin normal ; AST ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN patient liver metastasis ) ; Alkaline phosphatase ≤ 2.5 time ULN ( ≤ 5 time ULN patient liver metastasis ) ; Albumin ≥ 3.0 mg/dL ; Ability take oral medication ; Ability understand willingness sign write informed consent document . Evidence histology tumor papillary serous adenocarcinoma endometrioid type endometrial carcinoma mixed histology tumor ; History hormonal therapy endometrial carcinoma 3 month ; History use progestins period longer 3 month indication , include endometriosis ; Concurrent maintenance corticosteroid ; Concurrent oral contraceptives/ Fertile patient must use effective barrier contraception ; Pregnancy determine pregnancy test nursing ; History bleeding ( i.e . disseminate intravascular coagulation clot factor deficiency ) ; Prior major surgery le 4 week prior start study ; Concurrent serious illness , opinion investigator , would place patient unreasonable risk study therapy ; Previous malignancy le 3 year ago situ carcinoma cervix , basal cell carcinoma squamous carcinoma skin ; History allergic reaction idiosyncrasy attributed progestin compound similar chemical structure sodium cridanimod lidocaine ; Known brain metastasis ; Other concurrent investigational agent ; Other concurrent anticancer therapy . Known carrier HIV .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Endometrial cancer</keyword>
	<keyword>Recurrent persistent endometrial carcinoma</keyword>
	<keyword>Progesterone Receptor Negative</keyword>
	<keyword>Sodium cridanimod</keyword>
	<keyword>Virexxa</keyword>
</DOC>